Introduction

Ba/F3 cells, also known by the synonyms BA/F3, BaF3, BAF3, and Baf3 (Cellosaurus accession CVCL_0161), are a murine interleukin-3 (IL-3)-dependent pro-B cell line derived from bone marrow. The line was first described by Palacios and Steinmetz in 1985 among a panel of continuously proliferating, IL-3-dependent bone marrow clones that carried the B-cell lineage marker B-220 and retained their immunoglobulin genes in germ-line configuration. ^[19] Originally reported to originate from a BALB/c mouse, subsequent SNP array profiling established that the line is in fact derived from a C3H mouse. ^[1] Since their development, Ba/F3 cells have become one of the most widely employed model systems in hematopoietic signalling research and oncology drug discovery. Their strict dependence on IL-3 for survival and proliferation makes them an exceptionally clean platform: introduction of an oncogenic kinase or fusion protein renders the cells factor-independent, providing a powerful and quantifiable readout. Researchers routinely exploit this property to characterise BCR-ABL fusion proteins, FLT3 mutations, JAK2 fusions, and many other clinically relevant kinase oncogenes, as well as to profile small-molecule kinase inhibitors in high-throughput formats.

Key Takeaways

• Ba/F3 is a murine IL-3-dependent pro-B cell line derived from C3H mouse bone marrow, catalogued under Cellosaurus accession CVCL_0161.
• IL-3 withdrawal provides a stringent selection assay: parental cells die, whereas cells expressing an active oncogenic kinase — or any other construct that supplies a constitutive growth signal — survive and proliferate.
• The line has been extensively used to study BCR-ABL fusion proteins, FLT3 mutations, JAK–STAT signalling, and cytokine receptor biology.
• Ba/F3 cells are increasingly adapted to high-throughput kinase inhibitor screening, making them a cornerstone of targeted cancer drug discovery. ^[2]
• Hundreds of derivative cell lines carrying defined oncogenic mutations have been generated from Ba/F3, covering EGFR, ALK, ROS1, RET, NTRK, FLT3, and many other clinically relevant targets.

What is Ba/F3?

Ba/F3 is a factor-dependent murine pro-B cell line established from C3H mouse bone marrow; donor sex and age are not recorded in the Cellosaurus data for this line. The parental line carries no known activating kinase mutations and requires exogenous IL-3 for survival. Its doubling time is approximately 20 hours under standard culture conditions. The line's primary defining characteristic is its strict IL-3 dependence, which means that any genetic manipulation conferring factor-independent growth can be detected rapidly and unambiguously. This property, combined with the absence of confounding endogenous kinase mutations, has made Ba/F3 cells an indispensable tool for dissecting the oncogenic potential of kinase fusions, point mutations, and constitutively active signalling molecules across haematopoietic and solid tumour biology. It should be noted that the absence of a mutation annotation is not the same as a genetically pristine background: Cellosaurus also records SNP array-derived variation data for this line.

SNP array profiling corrected a long-standing misattribution of this line's origin. Early literature described Ba/F3 as deriving from a BALB/c mouse, but genomic analysis confirmed a C3H origin. ^[1] Of 99 mouse cell lines examined in that study, Ba/F3 was the single line whose genetic background did not match its reported strain of origin; the discrepancy was independently confirmed by RIKEN, a distributor of the line, and a morphological comparison against other C3H-derived lines indicated that Ba/F3 is a distinct cell line rather than the product of cross-contamination. This finding underscores the importance of routine cell line authentication, particularly for mouse lines where STR profiling alone may be insufficient to distinguish inbred strains. Researchers using Ba/F3 should reference Cellosaurus accession CVCL_0161 to ensure unambiguous identification in publications.

Cell Culture Information

Advantages of Ba/F3 Cells

The most significant advantage of Ba/F3 cells is their binary, IL-3-dependent survival switch. In the absence of IL-3, parental Ba/F3 cells rapidly undergo apoptosis. Introduction of an oncogenic kinase or fusion protein rescues cells from death, enabling straightforward selection of stably transformed clones without complex reporter constructs. This property has been exploited in numerous assay formats, from classic colony survival assays to modern high-throughput proliferation screens for compound profiling. ^[2] The simplicity and robustness of the readout make Ba/F3-based assays a widely used first-pass system for ranking kinase inhibitor potency, although absolute potency values remain assay- and laboratory-dependent and should be compared across studies with care. ^[21]

Ba/F3 cells are also genetically malleable and straightforward to transfect or transduce. Retroviral, lentiviral, and electroporation-based delivery of expression constructs all yield stably expressing sublines efficiently. This has enabled the generation of hundreds of derivative lines carrying clinically relevant mutations in targets such as EGFR, FLT3, BCR-ABL, EML4-ALK, and RET, among many others. The absence of confounding endogenous kinase mutations in the parental line ensures that phenotypic responses are attributable specifically to the introduced transgene. Additionally, the approximately 20-hour doubling time supports rapid experimental throughput, shortening assay timelines considerably compared to slower-growing primary cell cultures.

The Ba/F3 platform has proven uniquely suited to signal sequence discovery applications. Kojima and Kitamura exploited a constitutively active cytokine receptor construct to redirect Ba/F3 growth dependence towards cell-surface localisation of signal-peptide-bearing proteins, allowing large-scale cDNA screening to identify secreted and membrane-targeted gene products. ^[3] This creative application illustrates how the IL-3 dependence of Ba/F3 cells can be repurposed well beyond straightforward kinase oncogene work, establishing the line as a versatile genetic screening platform.

Limitations of Ba/F3 Cells

Despite their many advantages, Ba/F3 cells carry inherent biological limitations that must be considered when interpreting experimental data. As a murine pro-B cell line, they lack many signalling adaptors and co-receptors present in human cancer cells. Inhibitor potency values and downstream signalling responses observed in Ba/F3 cells may not accurately reflect activity in primary human tumour cells or patient-derived material. Researchers studying resistance to targeted therapies for lung adenocarcinoma, for example, must validate Ba/F3-based findings in more physiologically relevant human cell models before drawing clinical conclusions.

The line's genomic background has also been subject to mischaracterisation. For decades, Ba/F3 was attributed to a BALB/c origin, but SNP array profiling demonstrated that it originates from a C3H mouse. ^[1] The same study found evidence of aneuploidy in roughly 42% of the murine cell lines examined, including a substantial fraction of lines derived from normal rather than tumour tissue; Ba/F3 itself was flagged for misidentification rather than for copy number change, but the general finding illustrates how readily karyotypic drift accumulates in culture. Such instability at high passage numbers could influence signalling outcomes, drug sensitivity measurements, and the reproducibility of transformed phenotypes. Researchers should therefore work at low passage numbers and authenticate their stocks routinely.

Finally, Ba/F3 cells do not recapitulate the full tumour microenvironment or the stromal interactions present in haematological malignancies. They also lack endogenous expression of many human signalling components, meaning that co-receptor interactions important for oncogene function may be absent or divergent. Studies of complex multi-subunit cytokine receptors or receptors requiring glycosylation-dependent signalling may need complementary human cell systems to achieve biologically valid conclusions. Despite these caveats, Ba/F3 cells remain a powerful and widely accepted first-line tool in kinase biology.

View full specifications and order

Applications

Kinase Drug Discovery and Oncogene Screening

Ba/F3 cells have become the dominant cellular platform for kinase-targeted drug discovery. Warmuth and colleagues provided a comprehensive assessment of the Ba/F3 system for this purpose, describing how the IL-3 independence assay can be adapted to high-throughput formats to evaluate both the oncogenic potency of kinase mutations and the ability of small-molecule kinase inhibitors to reverse factor-independent growth. ^[2] The review highlighted that Ba/F3 cells accommodate a remarkable breadth of oncogenic kinases, making them a universal platform for initial profiling of cancer-associated kinome variants before proceeding to more complex human cell models.

The signal sequence trap developed by Kojima and Kitamura demonstrated that Ba/F3 cells can be used not only for kinase oncogene work but also for functional cDNA library screening. ^[3] By coupling a constitutively active cytokine receptor to signal-peptide function, a single pilot experiment yielded 150 previously known clones — all encoding secreted or cell-surface proteins — alongside 48 novel cDNA clones, including type II membrane proteins that had escaped earlier signal sequence trap strategies. This approach illustrates the scalability of the Ba/F3 platform beyond classical drug target validation.

The extreme diversity of derivative Ba/F3 lines now catalogued in Cellosaurus — spanning hundreds of EGFR variants, ALK fusions, RET rearrangements, NTRK fusions, and resistance mutations — underscores how the parental Ba/F3 line has become a foundational chassis for precision oncology research. Each derivative line preserves the clean IL-3-dependent background while adding a single defined genetic variable, enabling systematic structure–activity relationship studies at the cellular level.

FLT3 Mutations and Acute Myeloid Leukaemia

One of the most impactful applications of Ba/F3 cells has been the characterisation of FLT3 (fms-like tyrosine kinase 3) mutations in acute myeloid leukaemia (AML). Internal tandem duplication of FLT3 is among the most frequent oncogenic lesions in AML, reported in roughly 20% to 30% of cases depending on the cohort and detection method. ^[4][20] Hayakawa and colleagues demonstrated that tandem-duplicated FLT3, introduced into the two IL-3-dependent lines 32D and Ba/F3, constitutively activates both STAT5 and MAP kinase and confers autonomous, IL-3-independent growth, while wild-type FLT3 supported only minimal proliferation even under continuous ligand stimulation. ^[4] This landmark study established Ba/F3 cells as a primary functional assay system for validating FLT3 mutations and remains a methodological reference for the field.

Subsequent work has built extensively on this foundation. Studies of core fucosylation showed that CRISPR/Cas9 knockout of the Fut8 gene in Ba/F3 cells expressing wild-type FLT3 was sufficient to drive IL-3-independent proliferation — an effect not seen in parental cells — accompanied by increased tyrosine phosphorylation and activation of STAT5, AKT and ERK, and by ligand-independent FLT3 dimerisation. ^[20] This revealed a glycosylation layer of regulation not previously appreciated for this receptor. Resistance to the FLT3 inhibitor gilteritinib has also been interrogated in Ba/F3 FLT3-ITD models, where resistance at clinically achievable drug concentrations typically required multiple secondary mutations, several of them previously unreported. ^[21] The same work systematically weighed the strengths and limitations of Ba/F3 FLT3-ITD models, noting that while the platform is well suited to identifying and ranking resistance mutations, it does not replicate the complex bone marrow niche that shapes resistance in patients.

BCR-ABL Biology and Chronic Myeloid Leukaemia

Ba/F3 cells transfected with BCR-ABL fusion proteins have been instrumental in understanding the molecular biology of chronic myeloid leukaemia (CML). Canitrot and colleagues used Ba/F3 cells expressing the p190 and p210 BCR-ABL isoforms to demonstrate that BCR-ABL confers a mutator phenotype, increasing spontaneous mutation frequency three- to five-fold compared to parental cells, and that this genomic instability was associated with enhanced expression of DNA polymerase beta. ^[6] This finding provided a mechanism by which BCR-ABL might drive disease progression from chronic phase CML to acute myeloid leukaemia.

The adapter protein CRKL, one of the major tyrosine phosphoproteins in leukaemic neutrophils from CML patients, was studied in Ba/F3 cells by Uemura and colleagues. ^[7] Cells overexpressing full-length CRKL showed increased adhesion to fibronectin and altered morphology on fibronectin-coated surfaces, whereas deletion mutants lacking either the SH2 or the N-terminal SH3 domain did not — indicating that both domains are required for the effect. Adhesion was blocked by an anti-beta1 integrin antibody, although CRKL overexpression did not change beta1 integrin surface expression or spontaneously induce its activation epitope. These experiments implicate CRKL in signalling pathways that regulate integrin-mediated adhesion downstream of BCR-ABL.

Together, these BCR-ABL studies exemplify how Ba/F3 cells enable clean dissection of oncogene-driven signalling by removing the complexity of endogenous kinase activity. The platform continues to support characterisation of resistance mutations to BCR-ABL inhibitors, with dedicated Ba/F3 BCR-ABL and BCR-ABL-T315I derivative lines now available for direct inhibitor profiling in the context of clinically relevant resistance genotypes.

JAK–STAT Signalling Pathways

Ba/F3 cells have served as a primary model for dissecting which signalling events downstream of cytokine receptors are actually required for growth. Liu and colleagues constructed a chimeric molecule (beta/JAK2) consisting of the betac extracellular and transmembrane regions fused to JAK2 and expressed it in Ba/F3 cells. ^[8] The chimera was constitutively phosphorylated and sufficient to drive IL-3-independent survival and proliferation. Notably, STAT5, Shc and SHP-2 were not phosphorylated in these cells and beta-casein and c-fos promoter activity was not enhanced, while c-myc transcription was constitutively activated. The authors concluded that JAK2 activation alone suffices for survival and proliferation and that STAT5 and MAP kinase activation are not required for these particular outputs — a useful reminder that factor-independent growth in Ba/F3 cells does not by itself imply STAT activation.

The role of STAT5 in IFN-alpha signalling was examined in Ba/F3 cells by Jaster and colleagues, who showed that IFN-alpha activates STAT5A and STAT5B DNA binding but that IL-3 is a far more potent inducer of both isoforms. ^[9] A dominant-negative JAK2 mutant suppressed IL-3-driven but not IFN-alpha-driven STAT5 activation, revealing that the two cytokines engage independent upstream mechanisms to converge on the same transcription factor; the authors nevertheless concluded that STAT5 is not pivotal for IFN-alpha signalling in this system.

Constitutive JAK–STAT activation has been modelled in Ba/F3 cells using the TEL–JAK2 fusion protein, an oncogenic fusion associated with T-cell acute lymphoblastic leukaemia. Ho and colleagues showed that fusion of the TEL pointed domain to the functional JAK2 kinase (JH1) domain converted Ba/F3 cells to factor-independence, whereas fusion to the pseudokinase (JH2) domain or to a kinase-inactive JH1 domain did not; active constructs drove constitutive tyrosine phosphorylation of STAT1, STAT3 and STAT5. ^[5] More recently, methotrexate was found to suppress TEL–JAK2, STAT3 and STAT5 phosphorylation in Ba/F3 cells through a folate metabolism-dependent mechanism: the effect was reversed by folinic acid, reproduced by CRISPR/Cas9 knockout of dihydrofolate reductase, and not mimicked by 5-fluorouracil. ^[22]

IL-4 signalling through STAT6 was investigated by Gingras and colleagues, who demonstrated that p300/CBP coactivators are required for STAT6-mediated transcriptional induction and that overexpression of p300/CBP potentiates IL-4-driven reporter gene activity. ^[10] Most of that work was performed in COS7 and HeLa cells; Ba/F3 cells contributed the key endogenous evidence, namely the co-immunoprecipitation of native STAT6 together with CBP.

Cytokine Receptor Signalling and Haematopoietic Cell Biology

The GM-CSF/IL-3/IL-5 receptor system has been extensively mapped using Ba/F3 cells. Itoh and colleagues performed systematic mutational analysis of the eight cytoplasmic tyrosine residues of the common beta subunit (betac), expressing a series of tyrosine-to-phenylalanine mutants together with the wild-type human alpha subunit in Ba/F3 cells to determine which residues mediate specific signalling outputs. ^[12] Reviewing a parallel mutagenesis series, Okuda and colleagues reported that mutation of all eight cytoplasmic tyrosines in GMR-beta reduced phosphorylation of the receptor itself, SHP2 and SHC but did not ablate short-term proliferative signalling or JAK2 and STAT5 phosphorylation, illustrating a hierarchy of receptor domain functions. ^[13] The RON receptor tyrosine kinase was shown to engage the IL-3 betac receptor pathway in Ba/F3 cells to induce morphological changes involving F-actin redistribution and unique nuclear shape changes, revealing cross-talk between receptor tyrosine kinase and cytokine receptor systems. ^[14]

Receptor subdomain requirements have also been dissected for the IL-2 receptor. Using transfected Ba/F3 lines, Hunt and colleagues identified the acidic domain and the membrane-proximal serine-rich region of the IL-2 receptor beta chain as necessary for activation of p38 and p54 MAP kinases, with Tyr338 — the Shc binding site — serving as a critical intermediary. ^[11] Because the acidic domain is dispensable for IL-2-driven proliferation, the authors concluded that neither p38 nor p54 MAP kinase activation is actually required for IL-2-driven growth of Ba/F3 cells, a dissociation that also held for primary T cells.

Cell cycle regulation in haematopoietic progenitors has also been studied using Ba/F3 cells. Mahmud and colleagues demonstrated that TGF-beta1 retarded G1-to-S phase progression in Ba/F3 cells, associating this growth deceleration with upregulation of Bcl-2 protein and the CDK inhibitor p27. ^[15] IL-4 synergism with activated Raf-1 to drive long-term Ba/F3 proliferation was studied by Levings and colleagues, who found that IL-4 alone could not support growth but could cooperate with activated Ras or Raf-1 to sustain continuous proliferation comparable to IL-3. ^[16]

Engineered receptor switching systems have exploited Ba/F3 IL-3 dependence for gene therapy applications. Kume and colleagues developed a G-CSF receptor fused to bacterial gyrase B (GcrGyr), in which the dimerising antibiotic coumermycin triggered IL-3-independent Ba/F3 proliferation as a proof-of-concept selective amplifier gene system for expanding genetically modified haematopoietic cells. ^[17] Similarly, an IL-11 and soluble IL-11 receptor fusion protein was shown to act as a superagonist on gp130-transfected Ba/F3 cells lacking membrane-bound IL-11 receptor alpha, demonstrating that soluble receptor components can functionally substitute for transmembrane subunits. ^[18]

Conclusion

Ba/F3 cells (CVCL_0161) represent one of the most versatile and widely validated murine cell line platforms in modern biomedical research. Their strict IL-3 dependence provides an elegant and reproducible functional assay for oncogenic kinases — including BCR-ABL fusion proteins, FLT3 mutations, and JAK2 fusions — and for small-molecule kinase inhibitors with clinical relevance to chronic myeloid leukaemia, acute myeloid leukaemia, precursor cell lymphoblastic leukaemia-lymphoma, and lung adenocarcinoma. Decades of research have established JAK–STAT signalling, cytokine receptor biology, and haematopoietic cell regulation as core domains of Ba/F3 application. The line's adaptability has enabled the creation of hundreds of derivative models bearing defined resistance mutations, making it indispensable in targeted therapy development. If you are looking to establish or expand your kinase biology or drug discovery programme, Ba/F3 cells are available at cytion.com — visit the product page to enquire or place an order today.

Key Publications

1. Didion JP, Buus RJ, Naghashfar Z (2014) SNP array profiling of mouse cell lines identifies their strains of origin and reveals cross-contamination and widespread aneuploidy. BMC Genomics. PMID: 25277546
2. Warmuth M, Kim S, Gu XJ (2007) Ba/F3 cells and their use in kinase drug discovery. Current Opinion in Oncology. PMID: 17133113
3. Kojima T, Kitamura T (1999) A signal sequence trap based on a constitutively active cytokine receptor. Nature Biotechnology. PMID: 10331810
4. Hayakawa F, Towatari M, Kiyoi H (2000) Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. PMID: 10698507
5. Ho JM, Beattie BK, Squire JA (1999) Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. PMID: 10361134
6. Canitrot Y, Lautier D, Laurent G (1999) Mutator phenotype of BCR–ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. PMID: 10348341
7. Uemura N, Salgia R, Ewaniuk DS (1999) Involvement of the adapter protein CRKL in integrin-mediated adhesion. Oncogene. PMID: 10362355
8. Liu CB, Itoh T, Arai K (1999) Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells. The Journal of Biological Chemistry. PMID: 10037724
9. Jaster R, Tschirch E, Bittorf T (1999) Role of STAT5 in interferon-alpha signal transduction in Ba/F3 cells. Cellular Signalling. PMID: 10376805
10. Gingras S, Simard J, Groner B (1999) p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6. Nucleic Acids Research. PMID: 10373589
11. Hunt AE, Lali FV, Lord JD (1999) Role of interleukin (IL)-2 receptor beta-chain subdomains and Shc in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase activation. The Journal of Biological Chemistry. PMID: 10066828
12. Itoh T, Liu R, Arai K (1999) Differential influence of tyrosine residues of the common receptor beta subunit on multiple signals induced by human GM-CSF. The Journal of Allergy and Clinical Immunology. PMID: 10329850
13. Okuda K, Foster R, Griffin JD (1999) Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor. Annals of the New York Academy of Sciences. [Review] PMID: 10372132
14. Mera A, Suga M, Ando M (1999) Induction of cell shape changes through activation of the interleukin-3 common beta chain receptor by the RON receptor-type tyrosine kinase. The Journal of Biological Chemistry. PMID: 10336478
15. Mahmud N, Katayama N, Nishii K (1999) Possible involvement of bcl-2 in regulation of cell-cycle progression of haemopoietic cells by transforming growth factor-beta1. British Journal of Haematology. PMID: 10233423
16. Levings MK, Bessette DC, Schrader JW (1999) Interleukin-4 synergizes with Raf-1 to promote long-term proliferation and activation of c-jun N-terminal kinase. Blood. PMID: 10339476
17. Kume A, Ito K, Ueda Y (1999) A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells. Biochemical and Biophysical Research Communications. PMID: 10381335
18. Pflanz S, Tacken I, Grötzinger J (1999) A fusion protein of interleukin-11 and soluble interleukin-11 receptor acts as a superagonist on cells expressing gp130. FEBS Letters. PMID: 10350068
19. Palacios R, Steinmetz M (1985) Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell. PMID: 3924409
20. Duan C, Fukuda T, Isaji T (2020) Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system. The FASEB Journal. PMID: 31908039
21. Yang J, Friedman R (2025) Strengths and limitations of Ba/F3 cells in modelling FLT3-driven AML resistance. Bioorganic & Medicinal Chemistry Letters. PMID: 41183623
22. Saito M, Takeda K, Yoshino M (2026) Methotrexate inhibits the TEL-JAK2-STAT pathway through a folate metabolism-dependent mechanism in Ba/F3 cells. International Immunopharmacology. PMID: 42287956